Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients with Impaired Renal Function
2020-001247-12Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by University Medical Center Groningen. Primary endpoint: Change in 24-hour sodium excretion. Started Sep 2020; status: active.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-001247-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001247-12.